Upstream Bio, Inc.
NASDAQ:UPB · NASDAQ Global Select
+$0.10 today
Vol 0.79M · Avg 0.66M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-42.2%
avg -4.1%
ROIC
-47.0%
avg -68.5%
ROA
-40.5%
avg -50.1%
Analysis
ROA is currently the strongest return metric at -40.5% versus its period average of -50.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
E. Rand Sutherland | Chief Executive Officer & Director | $1.00M | — | 56 | $70,812.00 | 0.13% |
Aaron Deykin | Chief Medical Officer and Head of Research & Development | $741,800.00 | — | 59 | $33,197.00 | 0.06% |
Michael Paul Gray | Chief Financial Officer & Chief Operating Officer | $706,300.00 | — | 55 | $28,795.00 | 0.05% |
Allison Ambrose | Senior Vice President, General Counsel & Secretary | $59,792.00 | — | 41 | $16,048.00 | 0.03% |
Adam Houghton | Chief Business Officer | — | — | 55 | $23,601.00 | 0.04% |
Meggan Buckwell | Director of Corporate Communications & Investor Relations | — | — | — | — | — |
Mersedeh Miraliakbari | Senior Vice President of Regulatory Affairs & Quality | — | — | — | — | — |
Stacy Price | Chief Technology Officer | — | — | 57 | — | — |
Lisa Fiering | Senior Vice President of People & Culture | — | — | — | — | — |
Fang Xie | Vice President & Head of Biometrics | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
10
$77,192.77
Net Sentiment
$77,192.77
Net selling
Most Active
GRAY MICHAEL
2 transactions
Analysis
Insiders reported 0 buys worth $0.00 and 10 sells worth $77,192.77 over the last 12 months. That adds up to net selling of $77,192.77. GRAY MICHAEL was the most active insider with 2 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | +33.0% | +91.7% (5yr)6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Recent growth has been strongest in Revenue at +33.0% over three years. Forward estimates point to Revenue at +91.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Spyre Therapeutics, Inc.
NASDAQ:SYRE
$5.34B
Terns Pharmaceuticals, Inc.
TERN
$4.77B
Relay Therapeutics, Inc.
NASDAQ:RLAY
$2.78B
Pharvaris N.V.
NASDAQ:PHVS
$2.29B
Intellia Therapeutics, Inc.
NASDAQ:NTLA
$1.76B
Syndax Pharmaceuticals, Inc.
NASDAQ:SNDX
$1.68B
Novavax, Inc.
NASDAQ:NVAX
$1.50B
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLX
$1.30B
Wave Life Sciences Ltd.
NASDAQ:WVE
$1.19B
Zenas BioPharma, Inc.
NASDAQ:ZBIO
$883.04M
Who manages UPB?
Upstream Bio, Inc. (UPB) lists 10 active executives. The top listed executive is Adam Houghton, Chief Business Officer.
Are UPB insiders buying or selling?
Recent insider activity shows net buying of $16.38M.
Explore More
Continue the stock analysis
Jump to another research area for this company.